Chronic Idiopathic Constipation Therapeutics
1. Amitiza patent expiration
Treatment: Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable exci...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US8071613 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8114890 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US5284858 | SUCAMPO PHARMA LLC | Prostaglandins E and anti ulcers containing same |
Jul, 2014
(11 years ago) | |
| US8088934 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
May, 2021
(4 years ago) | |
| US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(3 years ago) | |
| US6583174 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6414016 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US7417067 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US8097649 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(3 years ago) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 3 months ago) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(4 months ago) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(1 year, 9 months from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
2. Linzess patent expiration
Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating of irritable bowel syndrome with constipation (ibs...
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(7 months from now) | |
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(5 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(5 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(7 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(5 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US7304036 (Pediatric) | ABBVIE | NA |
Feb, 2027
(1 year, 1 month from now) | |
|
US8748573 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | NA |
Feb, 2034
(8 years from now) | |
|
US8933030 (Pediatric) | ABBVIE | NA |
Aug, 2031
(5 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
3. Trulance patent
expiration
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; chronic idiopathic constipation; Irritable ...
TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(3 years ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(2 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(3 years ago) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US12146003 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(6 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents